Small Centers with Big Ventures: Autologous Stem Cell Transplantation Survival Data
- PMID: 31030464
- PMCID: PMC6948904
- DOI: 10.31557/APJCP.2019.20.4.987
Small Centers with Big Ventures: Autologous Stem Cell Transplantation Survival Data
Abstract
We present the first-ever autologous stem cell transplantation (ASCT) outcome data from a secondary-care healthcare facility. Albeit exact details of patient and disease characteristics and co-morbidity scores for all patients are not available, the engraftment and survival data is very similar to those published from large tertiary-care cancer centres, both regionally and internationally. Transplant Related Mortality (TRM) of 3.1% is within the expected range and includes a patient who died of acute drug reaction (ADR) during conditioning chemotherapy, prior to the ASCT. Furthermore, cyclophosphamide mobilization chemotherapy is given in the outpatient setting. This study is important in terms of healthcare resource optimization as well as patients’ convenience and highlights that ASCT can be performed in a safe and effective manner with comparable survival rates even at a DGH, provided the centre stays abreast with the recent developments and can offer its patients with standard of care treatment of the era.
Keywords: Outcome analysis; autologous stem cell transplantation; district general hospital; secondary care center.
Creative Commons Attribution License
Figures
Similar articles
-
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.Biol Blood Marrow Transplant. 2017 Jan;23(1):38-43. doi: 10.1016/j.bbmt.2016.09.024. Epub 2016 Oct 3. Biol Blood Marrow Transplant. 2017. PMID: 27713090 Free PMC article.
-
BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients.Ann Hematol. 2017 Mar;96(3):421-429. doi: 10.1007/s00277-016-2900-y. Epub 2016 Dec 24. Ann Hematol. 2017. PMID: 28011985
-
Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.Oncologist. 2018 May;23(5):624-630. doi: 10.1634/theoncologist.2017-0499. Epub 2017 Dec 28. Oncologist. 2018. PMID: 29284757 Free PMC article.
-
Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.Crit Rev Oncol Hematol. 2014 Feb;89(2):248-61. doi: 10.1016/j.critrevonc.2013.08.016. Epub 2013 Sep 8. Crit Rev Oncol Hematol. 2014. PMID: 24075060 Review.
-
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.Semin Oncol. 2002 Feb;29(1 Suppl 2):56-69. Semin Oncol. 2002. PMID: 11842390 Review.
References
-
- Abid MB, Christopher D, Abid MA, et al. Safety and cost-effectiveness of outpatient autologous transplantation for multiple myeloma in Asia: single-center perspective from Singapore. Bone Marrow Transplant. 2017;52:1044–6. - PubMed
-
- Auner HW, Szydlo R, Hoek J, et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant. 2015;50:209–15. - PubMed
-
- Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111:2521–610. - PubMed
-
- Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Eng J Med. 2003;348:1875–83. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials